Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
37.9M
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
3.3M
-
Shares change
-
-133K
-
Total reported value, excl. options
-
$9.05M
-
Value change
-
-$406K
-
Put/Call ratio
-
0
-
Number of buys
-
16
-
Number of sells
-
-16
-
Price
-
$2.74
Significant Holders of Anixa Biosciences Inc - Common Stock (ANIX) as of Q1 2022
48 filings reported holding ANIX - Anixa Biosciences Inc - Common Stock as of Q1 2022.
Anixa Biosciences Inc - Common Stock (ANIX) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.3M shares
of 37.9M outstanding shares and own 8.72% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1.3M shares), UBS Group AG (598K shares), GEODE CAPITAL MANAGEMENT, LLC (269K shares), RENAISSANCE TECHNOLOGIES LLC (225K shares), Long Focus Capital Management, LLC (116K shares), STATE STREET CORP (102K shares), BlackRock Inc. (102K shares), Bank of New York Mellon Corp (98.7K shares), MORGAN STANLEY (67.1K shares), and RAYMOND JAMES & ASSOCIATES (65.6K shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.